Back
Bristol-Myers Squibb Co (BMY)
PharmaceuticalsBMY · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$59.12
−0.77%Weekly undervalued picks (like BMY)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$3.46
ROE
38.7%
Gross margin
72.0%
Debt/Equity
2.31x
Revenue growth
2.6%
Bristol-Myers Squibb Co — company intelligence
Earnings surprises
Q2 2026$2.04 vs $1.60 est+27.2%
Q1 2026$1.58 vs $1.43 est+10.4%
Q4 2025$1.26 vs $1.13 est+11.9%
Q3 2025$1.63 vs $1.52 est+6.9%
Analyst consensus · 35 analysts
15 Buy18 Hold2 Sell
Updated Oct 9, 2026
Insider activity · 90 days
0 buys5 sellsnet -34,100 shares
Massacesi CristianSell 6,249 · Sep 9, 2026
Short Bartie WendySell 633 · Sep 1, 2026
Short Bartie Wendyother 1,236 · Sep 1, 2026
Recent SEC filings
4 — Insider transaction reportSep 10, 2026
4 — Insider transaction reportSep 3, 2026
4 — Insider transaction reportAug 26, 2026
Latest news
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder — Yahoo · 2w ago
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? — Yahoo · 3w ago
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth — Yahoo · 3w ago
BMY vs. ARGX: Which Stock Is the Better Value Option? — Yahoo · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like BMY)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.